Hepatitis B is a liver disease caused by the hepatitis B virus (HBV), with severe and long-term complications such as cirrhosis, liver failure and liver cancer. The transmission of this virus occurs mainly through the blood or other body fluids of an infected person, sexual contact, needle sharing or through mother-to-child transmission during childbirth. It is a major health issue in the world today, with millions of people suffering from long-term infection which can have devastating consequences without effective control. The virus infects liver cells and induces inflammation, which can affect the normal function of the liver such as detoxification processes, protein synthesis and bile production within normal limits, which are vital for the health of the body in general. This inflammation, initially, may appear as an acute infection but for some people, the infection turns chronic and causes long-term damage to the liver.
The hepatitis B virus is a member of the Hepadnaviridae family, an entire family of viruses that target the liver. The virus has a small, circular DNA genome that is enclosed within a protein shell called a capsid. This capsid is protected by an outer lipid cover that contains surface antigens that are important for the virus to infect host cells. These surface antigens also have an important role in the immune response against the virus. Hepatitis B is special among viruses because it attacks liver cells, but at the same time, a part of its DNA becomes integrated into the host genetic material so that infection and sequelae occur in the long term.
In the acute phase of hepatitis B infection, it may not show any symptoms, so most patients do not exhibit it. And also, some patients develop symptoms one to six months after exposure. Symptoms include fatigue, abdominal pain, jaundice (icterus), dark urine, pale stools, and nausea. Symptoms can range from mild to very severe, with some patients experiencing mild discomfort, but most suffering significant debilitating illness, including acute liver failure, which can be fatal.
In most cases, acute infection is followed by self-healing, in which the immune system clears the virus from the body. But in some patients, the infection persists for up to six months; they are said to have chronic infection. The worst consequence of chronic hepatitis B is that it continues to replicate and destroy the liver over a long period of time. Chronic hepatitis B is associated with the development of cirrhosis, which is scarring of the liver tissue, as well as liver failure in more severe cases. Additionally, patients with chronic hepatitis B also have an increased risk of developing hepatocellular carcinoma, one of the most common and serious cancers worldwide.
Chronic hepatitis B disease depends on several factors including the age of infection and the intensity of the immune response. Infants and young children are more likely to develop chronic infection than adults. However, adults have the ability to clear the virus. Still, chronic infection can occur in adults who fail to mount an effective immune response against the virus. Such culprits include people with weakened immunity, such as HIV-infected individuals or being on immunosuppressive treatment. Chronic hepatitis B develops risk assessment for various factors, including the factors listed earlier.
Most of the transmission of hepatitis B occurs through blood-to-blood contact. Infection through unprotected sex with an infected person is highly common as this virus is found in semen, vaginal fluids, and other bodily fluids. Another common mode of transmission is sharing needles and accessories among injecting drug users. Blood transfusion of infected blood products is also a mode of use which is a rare case of transmission. Hepatitis B is less likely to occur in areas with strict blood screening practices. The infection can also spread vertically from an infected mother to her baby during labor and delivery.
There are various ways to prevent hepatitis B infection. The most effective of these is vaccination. The hepatitis B vaccine is safe and is considered highly effective in preventing this infection. Typically, the vaccine is given as a complete regimen consisting of three or four shots, the first of which is given soon after birth, followed by doses in the following months. Furthermore, it has gained momentum internationally and has reduced the incidence of new infections to a significant level compared to areas with high hepatitis B transmission rates.
Other prevention measures are, for example, ensuring safe sex with the use of condoms, not sharing needles or other injections, importing blood products from blood banks with high screening for the virus. In addition, routine screening for pregnant women also includes potential hepatitis B patients, for whom preventive treatments are available in terms of risk reduction by vertical infection transmission in case the mother is infected. People who are at high risk of being infected, such as health workers or people with different sexual partners, may be advised to get tested and screened for hepatitis B periodically.
Hepatitis B is diagnosed primarily through blood tests that show whether the virus is present in the blood and/or whether the immune system has been activated in response to the virus. The most important of these tests is to detect the presence of hepatitis B surface antigen (HBsAg) in the blood which indicates that the virus itself is in circulation. Other tests can be used to check the viral load, level of liver damage, and status of acute versus chronic infection. They are important guidelines for treatment and monitoring disease progression.
Most people naturally clear the virus from their bodies and do not require antiviral medication for acute hepatitis B. In cases of severe acute hepatitis or in individuals at very high risk of complications, however, antivirals may be recommended to help manage the condition and reduce the likelihood of liver damage. Chronic hepatitis B is treated taking into account the agents used in treatment and generally aims to suppress virus activity while preventing additional liver injury. This involves a variety of antiviral agents—nucleoside and nucleotide analogs, which inhibit the replication of the virus. These agents are usually well tolerated but require long-term use to be effective in viral suppression. Sometimes they may be combined with some interferon therapy, although the latter appears to be rare due to its side effects.
To improve your understanding of chronic hepatitis B, antiviral treatment is complemented with close monitoring of people for signs of liver damage, development of cirrhosis and liver cancer. Regular blood tests and various imaging studies such as ultrasound and CT scans help determine liver function and liver tissue changes in those patients. Liver biopsy is performed for advanced liver disease conditions to assess the extent of liver damage. Treatment of liver cancer may include surgery, liver transplantation or chemotherapy depending on the stage of onset and progression of the disease.
Management of hepatitis B requires long-term care and monitoring, especially in people who have chronic infection. Regular follow-up visits with a healthcare provider allow early detection of complications as well as suppression of the virus. Although a cure for hepatitis B is not available today, monitoring along with proper treatment can help many people suffering from this disease lead normal lives without being affected by its severe effects. Effective management of hepatitis B mainly involves early detection, vaccination, and proper antiviral therapy.
A very serious liver infection caused by hepatitis B virus, which produces acute or chronic liver disease. The mode of transmission is through contact with infected blood and bodily fluids. The symptoms produced upon exposure to the agent can range from mild to severe. It causes long-term liver damage and has the potential to develop into liver cancer. There is no cure for hepatitis B yet; preventive measures by vaccination and antiviral treatment really help in managing it and avoiding complications. Longitudinal surveillance and early intervention are critical to optimise outcomes for individuals with hepatitis B. The world’s efforts to tackle hepatitis B through vaccination and public health initiatives are progressing rapidly, but education, screening, and treatment remain essential to reduce the burden of this disease worldwide.
